ROSSARI Rossari Biotech Q1 FY27 results (Apr–Jun 2026) and concall
Rossari Biotech Limited reported its highest ever quarterly revenue and EBITDA in Q1 FY27, with consolidated revenue growing 28% YoY to ₹697.2 crores. This growth was broad-based across all core segments and supported by international expansion. However, EBITDA margins compressed to 11.6% due to subdued institutional/consumer businesses, raw material volatility, and freight costs. The company is strategically rationalizing non-core assets and focusing on new product development to improve profitability and achieve a long-term EBITDA margin target of 15%.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q1 FY27: revenue up 31.7%, net profit up 30.8% against the same quarter last year.
| Line item | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|
| Revenue | 368 | 427 | 366 | 420 | 451 +23% | 516 +21% | 482 +32% |
| EBITDA | 50 | 52 | 44 | 50 | 50 +0% | 64 +23% | 56 +27% |
| Net profit | 31 | 32 | 26 | 31 | 31 +0% | 55 +72% | 34 +31% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
